Started at initial point of interest (IP list and to a lesser...

Started at initial point of interest (IP list and to a lesser degree - top shareholders).

Initial Findings

1. Ionis drug patents are now gone as expected. Makes an ongoing payaway/licence more questionable when all the IP is ANPs.

2. First mention of ODD protections (not with MS as it’s not considered a rare disease I gather)

3. Expected to see (some of) the DMD national phase patents going from “under examination” to “registered” or “granted” as they have had enough time (imo). I wonder if the change of patent lawyers last year had anything to do with handling of patent office objections (total speculation). Always thought they were going to struggle with prior art given the Pinto-Maritz(?) 2015 paper basically says ATL1102 should work on CD49b.